Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
In the recent past, concerns have raised regarding the potential risk of acute pancreatitis among type 2 diabetic patients using incretin-based drugs such as glucagon-like peptide 1 (GLP-1) analogs and dipeptidyl peptidase 4 (DPP-4) inhibitors. The aim of this study is to investigate the association between exposure to incretin-based drugs and the occurrence of pancreatitis reported in the French Pharmacovigilance Database. The case/non-case method was performed from serious adverse drug reactions (ADRs) involving antihyperglycemic agents (except insulin alone) reported to the French pharmacovigilance system between March 2008 (first marketing of an incretin-based drug in France) and March 2013. Cases were defined as reports of pancreatitis, and all other serious ADRs were considered non-cases. Disproportionality was assessed by calculating reporting odds ratios (ROR) adjusted for age, gender, history of pancreatitis, other antihyperglycemic drugs and other drugs associated with a higher risk of pancreatitis. Among 3,109 serious ADRs, 147 (4.7 %) reports of pancreatitis were identified as cases and 2,962 reports (95.3 %) of other ADRs as non-cases. Among the cases, 122 (83.0 %) involved incretin-based drugs. Disproportionality was found for all incretin-based drugs (adjusted ROR: 15.7 [95 % CI 9.8-24.9]), all GLP-1 analogs (29.4 [16.0-53.8]), exenatide (28.3 [12.8-62.3]), liraglutide (30.4 [15.4-60.0]), all DPP-4 inhibitors (12.1 [7.3-20.0]), sitagliptin (12.4 [7.3-21.0]), saxagliptin (15.1 [4.3-52.7]), and vildagliptin (7.4 [3.1-17.6]). Temporal analysis found disproportionality for incretin-based drugs since their first year of marketing in France. Compared with other antihyperglycemic agents, use of incretin-based drugs is associated with an increased risk of reported pancreatitis in France.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, GLP-1RAs use may be associated with an increased risk of acute pancreatitis and thyroid cancer, and the FDA has warned the public about these AEs (10–12).”
From Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system (2022) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470 · cited 1×
“Recently, two large randomized controlled trials did not find any increased pancreatitis risk with saxagliptin and alogliptin [34, 35].”
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502 · cited 1×
“Recently, two large randomized controlled trials did not find any increased pancreatitis risk with saxagliptin and alogliptin [34, 35].”
Under-Reporting of Adverse Drug Reactions: A Systematic Review
Hazell, L., & Shakir, S. A. W. (2006) · Drug Safety · doi:10.2165/00002018-200629050-00003 · Cited by 1,931 · cited 1×
“Considering that the rate of pancreatitis associated with incretin-based drugs which are effectively reported to pharmacovigilance system could range from 5% to 20% [12], the 122 cases reported between 2008 and 2013 in France could hypothetically represent 610 to 2,440 actual cases.”
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 3×
“In order to study variation in reporting rate and the presence of a notoriety effect [11], we performed a year-by-year analysis and compared the RORs before and after March 2011 (when the first study suggesting a risk of pancreatitis in the FDA AERS database was published) [2].”
InfluentialQuantitative signal detection using spontaneous ADR reporting
Bate, A., & Evans, S. J. W. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1742 · Cited by 912 · cited 1×
“The ROR is used to compare the rate of exposure to incretin-based drugs in cases of pancreatitis versus that in non cases [8, 9].”
Montastruc, J., Sommet, A., Bagheri, H., & Lapeyre‐Mestre, M. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04037.x · Cited by 517 · cited 1×
“Despite the fact that the disproportionality approach cannot give quantitative risk assessment for a specific ADR (ROR cannot be interpreted as risk ratio), case/non case studies analyzing "real life" pharmacovigilance data have shown in the past to be useful to detect drug safety signals [24, 25].”
Self-citationSingh, S., Chang, H.-Y., Richards, T. M., Weiner, J. P., Clark, J. M., & Segal, J. B. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2720 · Cited by 467 · cited 1×
“68]) [41].”
Butler, A. E., Campbell-Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M., & Butler, P. C. (2013) · Diabetes · doi:10.2337/db12-1686 · Cited by 457
Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes
Noel, R. A., Braun, D. K., Patterson, R. E., & Bloomgren, G. L. (2009) · Diabetes Care · doi:10.2337/dc08-1755 · Cited by 435 · cited 1×
“Several studies showed an increased risk of pancreatitis in patients with type 2 diabetes suggesting a role of diabetes itself [21-23].”
Dore, D. D., Seeger, J. D., & Arnold Chan, K. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902820519 · Cited by 326
Cited by
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Case-non-case studies: principle, methods, bias and interpretation
Faillie, J.-L. (2019) · Therapies · doi:10.1016/j.therap.2019.01.006 · Cited by 336
Self-citationLiu, L., Chen, J., Wang, L., Chen, C., & Chen, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1043789 · Cited by 258
Drug-induced acute pancreatitis: a review.
Jones, M. R., Hall, O. M., Kaye, A. M., & Kaye, A. D. (2015) · PubMed · Cited by 251
Metadata
- Authors
- The French Pharmacovigilance Centers Network, Faillie, J.-L., Babai, S., Crépin, S., Bres, V., Laroche, M.-L., Le Louet, H., Petit, P., Montastruc, J.-L., & Hillaire-Buys, D.
- Affiliations
- Centre Hospitalier Universitaire de Montpellier (FR)
- Centre Hospitalier Universitaire de Limoges (FR)
- Inserm (FR)
- Corresponding author
- Faillie, Jean-Luc
- Venue
- Acta Diabetologica
- Published
- 2013-12-19
- Volume
- 51
- Issue
- 3
- Pages
- 491-7
- ISSN
- 0940-5429 (ISSN-L)
- 1432-5233
- OpenAlex
- W2031272997
- Cited by
- 70
- References
- 35
- Citations by year
- 2026: 2 · 2024: 4 · 2023: 5 · 2022: 2 · 2021: 1 · 2020: 2 · 2019: 5 · 2018: 6 · 2017: 8 · 2016: 8 · 2015: 16 · 2014: 11
- FWCI
- 9.18
- Type
- journal article
- Language
- en
- Open access
- green
- unilim.hal.science
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Acta Diabetologica (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Funders
- Agence Nationale de Sécurité du Médicament et des Produits de Santé
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- acute pancreatitis, GLP-1 analogues, DPP-4 inhibitors, incretin-based drugs, type 2 diabetes, serious adverse drug reactions, exenatide, liraglutide, sitagliptin, saxagliptin, vildagliptin, pharmacovigilance, drug safety, antidiabetic drugs, reporting odds ratio
- MeSH terms
- Adult, Aged, Aged, 80 and over, Diabetes Mellitus, Type 2, Female, France, Humans, Male, Middle Aged, Pancreatitis, Case-Control Studies, Databases, Factual, Glucagon-Like Peptide 1, Dipeptidyl-Peptidase IV Inhibitors, Pharmacovigilance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.